Abstract
Acute graft-versus-host disease (aGVHD) is a major cause of mortality after allogeneic stem cell transplantation. Although initial treatment with corticosteroids is effective in the majority of patients, 30â60% develop steroid resistance. Anti-thymocyte globulin (ATG) is commonly used as first-line therapy for steroid resistant (SR) aGVHD. However, data on its efficacy are limited. At two institutions we reviewed the results of treatment with ATG of 58 patients with SR aGVHD. Initial manifestations of aGVHD were treated with 2âmg/kg/day of methylprednisolone (MP). Equine ATG was administered as first-line therapy for SR aGVHD, a median of 9 days (range, 3 to 39) after initiation of MP. At the time of initiation of ATG, IBMTR severity indices B, C and D were observed in 6%, 40% and 54% of patients, respectively. Improvement was observed in 30% of patients treated with ATG. Skin disease was more likely to improve with ATG (79%), while progression of gut and liver aGVHD was observed in 40% and 66% of patients, respectively. Despite initial improvement, 52 patients (90%) died a median of 40 days after ATG therapy from progressive aGVHD and/or infection (74%), ARDS (15%), or relapse (11%). Only six patients (10%), three of whom had aGVHD limited to the skin at the time ATG was administered, are long-term survivors. We conclude that initial improvement of SR aGVHD occurs with ATG in a minority of patients, and very few patients become long-term survivors. Furthermore, this treatment is associated with a high rate of major complications. Bone Marrow Transplantation (2001) 27, 1059â1064.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ferrara JL, Deeg HJ . Graft-versus-host disease New Engl J Med 1991 324: 667â674
Rowlings PA, Przepiorka D, Klein JP et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade Br J Haematol 1997 97: 855â864
Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia New Engl J Med 1986 314: 729â735
Deeg HJ, Lin D, Leisenring W et al. Cyclosporine or cyclosporine plus methotrexate for prophylaxis of graft-versus-host disease: a prospective, randomized trial Blood 1997 89: 3880â3887
Ratanatharathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 1998 92: 2303â2314
Nash RA, Pineiro LA, Storb R et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors Blood 1996 88: 3634â3641
Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia New Engl J Med 1998 338: 962â968
Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment Blood 1991 77: 1821â1828
Weisdorf D, Haake R, Blazar B et al. Treatment of moderate acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome Blood 1990 75: 1024â1030
Van Lint MT, Uderzo C, Locasciulli A et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian group for bone marrow transplantation Blood 1998 92: 2288â2293
Kienast J, Ippolitti C, Mehra R et al. Dose-intensified anti-thymocyte globulin in steroid-resistant graft-versus-host disease after allogeneic marrow or blood stem cell transplantation Blood 1997 90: 104a (Abstr.)
Gluckman E, Devergie A, Marty M et al. Treatment of GVH with ATG Pathol Biol 1978 26: 51
Roy J, McGlave PB, Filipovich AH et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy Bone Marrow Transplant 1992 10: 77â82
Kienast J, Ippolitti C, Mehra R et al. Dose-intensified ATG in steroid-resistant graft-versus-host disease after allogeneic marrow or blood stem cell transplantation Blood 1997 90: 104a
McCaul KG, Nevill TG, Klingemann HG et al. Treatment of steroid-resistant graft-versus-host disease with thymoglobulin. IBMTR/ABMTR 1998 meeting, Abstr. G-7
Margolis J, Davidson R, Doherty G et al. Poor outcome in steroid-refractory GVHD with ATG treatment Blood 1999 94: 152a
Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk factors and outcome Blood 1990 75: 1024â1030
Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy of acute graft-versus-host disease: secondary treatment Blood 1991 77: 1821â1828
Winston DJ, Gale RP, Meyer DV et al. Infectious complications of human bone marrow transplantation Medicine 1979 58: 1â31
Nieman PE, Reeves W, Ray G et al. A prospective analysis of interstitial pneumonia and opportunistic viral infection among recipients of allogeneic bone marrow grafts J Infect Dis 1977 136: 754â767
Doney KC, Weiden PL, Storb R, Thomas ED . Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids Am J Hematol 1981 11: 1â8
Ringden O, Persson U, Gunnar S et al. Early diagnosis and treatment of acute human graft-versus-host disease Transplant Proc 1983 15: 1490â1494
Dugan MJ, DeFor TE, Steinbuch M et al. ATG plus corticosteroids therapy for acute graft-versus-host disease: predictors of response and survival Ann Hematol 1997 75: 41â46
Atkinson K Horowitz MM, Biggs JC et al. The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers Bone Marrow Transplant 1988 3: 5â10
Martin P, Nash R, Sanders J et al. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation Bone Marrow Transplant 1008 21: 273â279
Acknowledgements
We thank the physicians, nurses and staff at the Washington University (St Louis, MO) and City of Hope (Duarte, CA) who cared for the patients. We especially thank Carla Brewster and Kim Gilfillan for excellent data retrieval. We also thank Dr Philip Rowlings for providing survival estimates from the IBMTR database. We thank Mrs Ruby Morrissey for secretarial support in the preparation of this manuscript. This work was supported by NCIâPPGâCAâ30206 and NCIâCAâ33572.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Khoury, H., Kashyap, A., Adkins, D. et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 27, 1059â1064 (2001). https://doi.org/10.1038/sj.bmt.1703032
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703032
Keywords
This article is cited by
-
Letter to the Editor: Very low-dose antithymocyte globulin (thymoglobulin) is effective for steroid-refractory acute graft-versus-host disease involving the skin or gut after allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2022)
-
Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide
Annals of Hematology (2021)
-
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit
Bone Marrow Transplantation (2018)
-
EBMTâNIHâCIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment
Bone Marrow Transplantation (2018)
-
Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD
Bone Marrow Transplantation (2017)